Loading data for ARGX — first visit, this takes a few seconds.
argenx SE (ARGX)
NasdaqGS: ARGX
· Real-Time Price · USD
1,033.15
-20.31 (-1.93%)
At close: Sep 04, 2026, 8:00 PM
1,033.15
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
argenx SE (ARGX) Stock Price, Analysis & Data
No data available
| Bid | 1043.59 |
| Market Cap | 64.2B |
| Revenue (ttm) | 5.32B |
| Net Income (ttm) | 1.72B |
| -0.03 | |
| 26.25 | |
| 39.36 | |
| 26.28 | |
| P/B (ttm) | 191.91 |
| P/S (ttm) | 12.16 |
| Earnings Date | Oct 22, 2026 |
| Ask | 995 |
| Volume | 125,045 |
| Avg. Volume (20D) | 332,411 |
| Open | 1040.31 |
| Previous Close | 1053.46 |
| Day's Range | 1031.19 - 1048.43 |
| 52-Week Range | 661.85 - 1072.75 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative g...
Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2017
Employees 1,863
Stock Exchange NasdaqGS
Ticker Symbol ARGX
Website https://argenx.com
Financial Performance
In 2025, argenx SE's revenue was 4.15B, an increase of 89.64% compared to the previous year's 2.19B. Earnings were 1.29B, an increase of 55.1%.
Financial StatementsEarnings Surprise
argenx SE has released their quarterly earnings on Jul 23, 2026:
- Revenue of $1.52B misses estimates by $0, with 59.82% YoY growth.
- EPS of 7.32 exceeds estimates by 1.13, with 95.72% YoY growth.
argenx SE is scheduled to release its earnings on Oct 22, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2